The global Compensated Cirrhosis Type C market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Cirrhosis is scarring or fibrosis of the liver caused due to many types of liver diseases like chronic alcoholism and hepatitis. The liver carries out several functions, including detoxification of harmful substances body, cleaning the blood and making of the vital nutrients. Cirrhosis occurs in response to damage caused to your liver. Most common causes of Compensated liver cirrhosis are hepatitis B and C, diseases related to alcohol and NASH. Many chronic liver diseases develop gradually over time. The rate of progression of cirrhosis is usually slow in the early phases of the disease and then it accelerates after complications of cirrhosis arise. For the diagnosis of cirrhosis, liver biopsy is often required which provides information regarding the severity of the disease. Transient elastography (fibroscan) is a cost-effective technique for the screening of liver cirrhosis. Treatment for compensated cirrhosis should include treatment for HCV infection and can be treated by using direct antiviral agents. Diagnosis can be done by using esophagogastroduodenoscopy (EGD).
Compensated Cirrhosis Type C Market aims to provide a comprehensive presentation of the global market for Compensated Cirrhosis Type C, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Compensated Cirrhosis Type C. Compensated Cirrhosis Type C Market contains market size and forecasts of Compensated Cirrhosis Type C in global, including the following market information:
Global Compensated Cirrhosis Type C Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Antagonist Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Compensated Cirrhosis Type C include Gilead Sciences, Inc., AbbVie Inc., Novartis International AG, Intercept Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Alnylam Pharmaceuticals Inc., Cadila Healthcare Ltd and Sanofi S.A, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Compensated Cirrhosis Type C companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Compensated Cirrhosis Type C Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Compensated Cirrhosis Type C Market Segment Percentages, by Type, 2022 (%)
- Antagonist
- Antiviral Drugs
- Corticosteroids
- Chelating Agents
Global Compensated Cirrhosis Type C Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Compensated Cirrhosis Type C Market Segment Percentages, by Application, 2022 (%)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Drug Store
Global Compensated Cirrhosis Type C Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Compensated Cirrhosis Type C Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Compensated Cirrhosis Type C revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Compensated Cirrhosis Type C revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Gilead Sciences, Inc.
- AbbVie Inc.
- Novartis International AG
- Intercept Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Eli Lilly and Company
- Alnylam Pharmaceuticals Inc.
- Cadila Healthcare Ltd
- Sanofi S.A
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of Compensated Cirrhosis Type C, market overview.
Chapter 2: Global Compensated Cirrhosis Type C market size in revenue.
Chapter 3: Detailed analysis of Compensated Cirrhosis Type C company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Compensated Cirrhosis Type C in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
Industry Market Size
